January 3, 2024
(press release)
–
GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference. Conference Details: Presentation and Q&A Date: Monday, January 8, 2024 Time: 5:15 – 5:55 p.m. Pacific Standard Time (PST) Location: Westin St. Francis Hotel in San Francisco, California Moderator: Eric Joseph, Ph.D., Executive Director, Biotechnology Equity Research Novavax participants: John C. Jacobs, President and Chief Executive Officer Conference Event: Investor Meetings Date: Monday, January 8, 2024 Recordings About Novavax Contacts: Media SOURCE NOVAVAX, INC
A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Ali Chartan
240-720-7804
media@novavax.com
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.